January 4, 2012 9:50 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Jefferies issued a note today on Arena Pharmaceuticals (NASDAQ: ARNA) following results from a series of Lorcaserin studies. Lorcaserin is a weight-loss drug under development by Arena Pharmaceuticals.In the report, Jefferies writes, "Arena and Eisai (4523 JP,¥3,185, UNPF) provided mixed data from Lorcaserin studies of potential mechanisms for prolactin-mediated rat tumors, showing an inconsistent effect on precursors of mammary tumors but the ability to block these effects using prolactin-specific mechanisms. These data may prove favorable, but we remain cautious on lorcaserin's risk benefit profile."Jeffereies has an Underperform rating and $1.00 price target on Arena Pharmaceuticals. Shares of Arena Pharmaceuticals are currently trading at $2.02, up 5.21% from Tuesday's market close.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.